Jikei-Evaluation of basal insulin analogue on (nocturnal) glycemic variability with continuous glucose monitoring -existing basal insulin analogue versus Tresiba ; insulin degludec - a new basal insulin analogue, in basal-bolus treatment in type 2 diabetes-

Jikei-Evaluation of basal insulin analogue on (nocturnal) glycemic variability with continuous glucose monitoring -existing basal insulin analogue versus Tresiba ; insulin degludec - a new basal insulin analogue, in basal-bolus treatment in type 2 diabetes- - JET-2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013818

Enrollment

100

Registered

2014-04-26

Start date

2014-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

insulin degludec long-acting insulin analogue other than insulin degludec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes receiving Basal-bolus insulin therapy.

Exclusion criteria

Exclusion criteria: Type 1 diabetes

Design outcomes

Primary

Measure	Time frame
Continuous glucose value of 24 hours by CGM	—

Countries

Japan

Contacts

Public ContactRimei NIshimura

The Jikei University School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

rimei@jikei.ac.jp0334331111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026